Abeona Therapeutics (NASDAQ:ABEO) CEO Sells $131,000.00 in Stock

Abeona Therapeutics Inc. (NASDAQ:ABEO) CEO Vishwas Seshadri sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, September 30th. The shares were sold at an average price of $5.24, for a total transaction of $131,000.00. Following the completion of the transaction, the chief executive officer directly owned 1,190,067 shares in the company, valued at approximately $6,235,951.08. The trade was a 2.06% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Vishwas Seshadri also recently made the following trade(s):

• On Monday, September 29th, Vishwas Seshadri sold 19,274 shares of Abeona Therapeutics stock. The shares were sold at an average price of $5.39, for a total transaction of $103,886.86.
• On Wednesday, July 9th, Vishwas Seshadri sold 69,420 shares of Abeona Therapeutics stock. The shares were sold at an average price of $5.86, for a total transaction of $406,801.20.

Abeona Therapeutics Trading Up 1.7%

NASDAQ:ABEO opened at $5.41 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 6.65 and a current ratio of 6.73. The firm has a market cap of $277.42 million, a price-to-earnings ratio of 7.73 and a beta of 1.42. Abeona Therapeutics Inc. has a 52 week low of $3.93 and a 52 week high of $7.54. The firm has a 50-day moving average price of $6.36 and a two-hundred day moving average price of $5.92.

Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings data on Thursday, August 14th. The biopharmaceutical company reported $1.71 EPS for the quarter, beating the consensus estimate of ($0.39) by $2.10. The firm had revenue of $0.40 million during the quarter, compared to analysts’ expectations of $21.71 million. On average, equities analysts expect that Abeona Therapeutics Inc. will post -1.16 earnings per share for the current fiscal year.

Institutional Trading of Abeona Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Adage Capital Partners GP L.L.C. lifted its holdings in shares of Abeona Therapeutics by 14.2% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 3,072,985 shares of the biopharmaceutical company’s stock worth $17,455,000 after acquiring an additional 381,357 shares during the last quarter. Boone Capital Management LLC bought a new stake in shares of Abeona Therapeutics during the 2nd quarter worth $7,126,000. Geode Capital Management LLC lifted its holdings in shares of Abeona Therapeutics by 129.1% during the 2nd quarter. Geode Capital Management LLC now owns 1,105,862 shares of the biopharmaceutical company’s stock worth $6,282,000 after acquiring an additional 623,243 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Abeona Therapeutics by 255.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 831,132 shares of the biopharmaceutical company’s stock worth $4,721,000 after acquiring an additional 597,373 shares during the last quarter. Finally, 683 Capital Management LLC lifted its holdings in shares of Abeona Therapeutics by 11.1% during the 2nd quarter. 683 Capital Management LLC now owns 750,000 shares of the biopharmaceutical company’s stock worth $4,260,000 after acquiring an additional 75,000 shares during the last quarter. 80.56% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms have commented on ABEO. Weiss Ratings reiterated a “hold (c-)” rating on shares of Abeona Therapeutics in a research note on Saturday, September 27th. HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of Abeona Therapeutics in a research note on Monday, August 18th. Finally, Oppenheimer raised their price target on shares of Abeona Therapeutics from $19.00 to $20.00 and gave the stock an “outperform” rating in a research note on Friday, August 15th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $19.50.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.